106 related articles for article (PubMed ID: 20727673)
1. RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase.
Lee KH; Hur HS; Im SA; Lee J; Kim HP; Yoon YK; Han SW; Song SH; Oh DY; Kim TY; Bang YJ
Cancer Lett; 2010 Dec; 299(1):22-8. PubMed ID: 20727673
[TBL] [Abstract][Full Text] [Related]
2. RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer.
Wang ZG; Fukazawa T; Nishikawa T; Watanabe N; Sakurama K; Motoki T; Hatakeyama S; Omori O; Ohara T; Tanabe S; Fujiwara Y; Takaoka M; Shirakawa Y; Yamatsuji T; Tanaka N; Naomoto Y
Oncol Rep; 2010 Apr; 23(4):1167-72. PubMed ID: 20204306
[TBL] [Abstract][Full Text] [Related]
3. Cell cycle regulation of the G0/G1 transition in 5-fluorouracil-sensitive and -resistant human colon cancer cell lines.
McGinn CJ; Pestalozzi BC; Drake JC; Glennon MC; Kunugi K; Otterson G; Allegra CJ; Johnston PG; Kinsella TJ
Cancer J; 2000; 6(4):234-42. PubMed ID: 11038143
[TBL] [Abstract][Full Text] [Related]
4. Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease.
Zitzmann K; Rüden Jv; Brand S; Göke B; Lichtl J; Spöttl G; Auernhammer CJ
Cancer Lett; 2010 Sep; 295(1):100-9. PubMed ID: 20356670
[TBL] [Abstract][Full Text] [Related]
5. The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro.
Liu H; Zang C; Schefe JH; Schwarzlose-Schwarck S; Regierer AC; Elstner E; Schulz CO; Scholz C; Possinger K; Eucker J
Anticancer Res; 2011 Sep; 31(9):2713-22. PubMed ID: 21868512
[TBL] [Abstract][Full Text] [Related]
6. The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells.
Grozinsky-Glasberg S; Rubinfeld H; Nordenberg Y; Gorshtein A; Praiss M; Kendler E; Feinmesser R; Grossman AB; Shimon I
Mol Cell Endocrinol; 2010 Feb; 315(1-2):87-94. PubMed ID: 19815051
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: thymidylate synthase dependent and independent networks.
Wang W; McLeod HL; Cassidy J; Collie-Duguid ES
Cancer Chemother Pharmacol; 2007 May; 59(6):839-45. PubMed ID: 17119966
[TBL] [Abstract][Full Text] [Related]
8. Dihydropyrimidine dehydrogenase but not thymidylate synthase expression is associated with resistance to 5-fluorouracil in colorectal cancer.
Nita ME; Tominaga O; Nagawa H; Tsuruo T; Muto T
Hepatogastroenterology; 1998; 45(24):2117-22. PubMed ID: 9951876
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the mTOR/S6K signal is necessary to enhance fluorouracil-induced apoptosis in gastric cancer cells with HER2 amplification.
Tomioka H; Mukohara T; Kataoka Y; Ekyalongo RC; Funakoshi Y; Imai Y; Kiyota N; Fujiwara Y; Minami H
Int J Oncol; 2012 Aug; 41(2):551-8. PubMed ID: 22614071
[TBL] [Abstract][Full Text] [Related]
10. Akt and p53 are potential mediators of reduced mammary tumor growth by cloroquine and the mTOR inhibitor RAD001.
Loehberg CR; Strissel PL; Dittrich R; Strick R; Dittmer J; Dittmer A; Fabry B; Kalender WA; Koch T; Wachter DL; Groh N; Polier A; Brandt I; Lotz L; Hoffmann I; Koppitz F; Oeser S; Mueller A; Fasching PA; Lux MP; Beckmann MW; Schrauder MG
Biochem Pharmacol; 2012 Feb; 83(4):480-8. PubMed ID: 22142888
[TBL] [Abstract][Full Text] [Related]
11. Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines.
Johnston PG; Drake JC; Trepel J; Allegra CJ
Cancer Res; 1992 Aug; 52(16):4306-12. PubMed ID: 1643628
[TBL] [Abstract][Full Text] [Related]
12. Chronic exposure of colorectal cancer cells in culture to fluoropyrimidine analogs induces thymidylate synthase and suppresses p53. A molecular explanation for the mechanism of 5-FU resistance.
Subbarayan PR; Sarkar M; Nelson G; Benitez E; Singhal S; Ardalan B
Anticancer Res; 2010 Apr; 30(4):1149-56. PubMed ID: 20530421
[TBL] [Abstract][Full Text] [Related]
13. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
Gorshtein A; Rubinfeld H; Kendler E; Theodoropoulou M; Cerovac V; Stalla GK; Cohen ZR; Hadani M; Shimon I
Endocr Relat Cancer; 2009 Sep; 16(3):1017-27. PubMed ID: 19509067
[TBL] [Abstract][Full Text] [Related]
14. Detection and quantitation of thymidylate synthase mRNA in human colon adenocarcinoma cell line resistant to 5-fluorouracil by competitive PCR.
Shibata J; Aiba K; Shibata H; Minowa S; Horikoshi N
Anticancer Res; 1998; 18(3A):1457-63. PubMed ID: 9673356
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of 5-fluorouracil sensitivity by an rTS signaling mimic in H630 colon cancer cells.
Dolnick R; Wu Q; Angelino NJ; Stephanie LV; Chow KC; Sufrin JR; Dolnick BJ
Cancer Res; 2005 Jul; 65(13):5917-24. PubMed ID: 15994970
[TBL] [Abstract][Full Text] [Related]
16. Arsenic trioxide suppresses thymidylate synthase in 5-FU-resistant colorectal cancer cell line HT29 In Vitro re-sensitizing cells to 5-FU.
Subbarayan PR; Lee K; Ardalan B
Anticancer Res; 2010 Apr; 30(4):1157-62. PubMed ID: 20530422
[TBL] [Abstract][Full Text] [Related]
17. The role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil and antifolates.
Longley DB; Boyer J; Allen WL; Latif T; Ferguson PR; Maxwell PJ; McDermott U; Lynch M; Harkin DP; Johnston PG
Cancer Res; 2002 May; 62(9):2644-9. PubMed ID: 11980662
[TBL] [Abstract][Full Text] [Related]
18. [Detection of thymidylate synthase mRNA in 5-fluorouracil resistant human colon adenocarcinoma cells].
Shibata J; Aiba K; Shibata H; Minowa S; Horikoshi N
Gan To Kagaku Ryoho; 1994 Aug; 21(10):1613-8. PubMed ID: 8060136
[TBL] [Abstract][Full Text] [Related]
19. Induction of thymidylate synthase associated with multidrug resistance in human breast and colon cancer cell lines.
Chu E; Drake JC; Koeller DM; Zinn S; Jamis-Dow CA; Yeh GC; Allegra CJ
Mol Pharmacol; 1991 Feb; 39(2):136-43. PubMed ID: 1704999
[TBL] [Abstract][Full Text] [Related]
20. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Emura T; Suzuki N; Yamaguchi M; Ohshimo H; Fukushima M
Int J Oncol; 2004 Sep; 25(3):571-8. PubMed ID: 15289858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
